[1] Tang J T, Mao Y M. Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.J Dig Dis, 2017, 18(11): 607-617.
[2] Kanwar P, Kowdley K V. The metabolic syndrome and its influence on nonalcoholic steatohepatitis. Clin Liver Dis, 2016, 20(2): 225-243.
[3] Jacobs A, Warda A S, Verbeek J, et al. An overview of mouse models of nonalcoholic steatohepatitis: from past to present. Curr Protoc Mouse Biol, 2016, 6(2): 185-200.
[4] Wang Y J, Gong Z Q, Bi X M, et al. Correlation of plasma soluble cluster of differentiation 40 ligand, alpha fetoprotein a, and pregnancy-associated plasma protein a with carotid plaque in patients with ischemic stroke. Genet Mol Res, 2015, 14(3): 8091-8099.
[5] Rios-Toro J J, Marquez-Coello M, Garcia-Alvarez J M, et al. Soluble membrane receptors, interleukin 6, procalcitonin and c reactive protein as prognostic markers in patients with severe sepsis and septic shock. PLoS One, 2017, 12(4): e175254.
[6] 石翠翠,范建高. 美国非酒精性脂肪性肝病诊疗指南解读. 实用肝脏病杂志, 2017, 20(5): 646-648.
[7] 张兰华,邵琴,夏振娟. 非酒精性脂肪性肝病儿童血清25-(OH)D3和IL-17水平变化初步研究. 实用肝脏病杂志, 2019,22(4): 522-525.
[8] Zhi Y, Gao P, Xin X, et al. Clinical significance of scd163 and its possible role in asthma (review). Mol Med Rep, 2017, 15(5): 2931-2939.
[9] Bryant A K, Moore D J, Burdo T H, et al. Plasma soluble cd163 is associated with postmortem brain pathology in human immunodeficiency virus infection. AIDS, 2017, 31(7): 973-979.
[10] 信丰智,曹海霞,范建高. 胰高血糖素样肽-1改善非酒精性脂肪性肝病作用机制研究进展. 实用肝脏病杂志, 2018, 21(2): 313-316.
[11] 曾益林,倪永锐. 腹部超声对糖尿病合并非酒精性肝炎的筛查及相关因素. 世界华人消化杂志, 2016, 24(18): 2886-2891.
[12] Dekkema G J, Abdulahad W H, Bijma T, et al. Urinary and serum soluble cd25 complements urinary soluble cd163 to detect active renal anti-neutrophil cytoplasmic autoantibody-associated vasculitis: a cohort study. Nephrol Dial Transplant, 2019, 34(2): 234-242.
[13] Kameoka S, Kameyama T, Hayashi T, et al. Helicobacter pylori induces IL-1beta protein through the inflammasome activation in differentiated macrophagic cells. Biomed Res, 2016, 37(1): 21-27.
[14] Pilkington SM, Ogden S, Eaton L H, et al. Lower levels of interleukin-1beta gene expression are associated with impaired langerhans' cell migration in aged human skin. Immunology, 2018, 153(1): 60-70.
[15] Kitade H, Chen G, Ni Y, et al. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients,2017, 9(4): E387.
[16] Yki-Jarvinen H. Nutritional modulation of non-alcoholic fatty liver disease and insulin resistance. Nutrients, 2015, 7(11): 9127-9138.
[17] Chang ML, Hsu C M, Tseng JH, et al. Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease whereas leptin and adiponectin vary between genders. J Gastroenterol Hepatol, 2015, 30(2): 329-336.
[18] Saez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, et al. Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: a review of human clinical Trials. Int J Mol Sci, 2016, 17(6):512-516.
[19] Farzanegi P, Dana A, Ebrahimpoor Z, et al. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (nafld): roles of oxidative stress and inflammation. Eur J Sport Sci,2019,19(7): 994-1003.
[20] Kalinowski P, Paluszkiewicz R, Ziarkiewicz-Wróblewska B, et al. Liver function in patients with nonalcoholic fatty liver disease randomized to Roux-en-Y gastric bypass versus sleeve gastrectomy: A secondary analysis of a randomized clinical trial. Ann Surg,2017,266(5): 738-745.
[21] Negroni A, Colantoni E, Vitali R, et al. Nod2 induces autophagy to control aiec bacteria infectiveness in intestinal epithelial cells. Inflamm Res, 2016, 65(10): 803-813.
[22] Fujimura T, Sato Y, Tanita K, et al. Serum level of soluble cd163 may be a predictive marker of the effectiveness of nivolumab in patients with advanced cutaneous melanoma. Front Oncol, 2018, 8: 530. |